cobas® Cdiff

IVD For in vitro diagnostic use.
cobas Cdiff

Use left and right arrow keys to scroll between the tabs

Fast, accurate results to inform patient care

C. difficile infection (CDI) is the most common healthcare-associated infection worldwide, affecting approximately 500,000 Americans each year1 and resulting in an estimated $5.4 billion in additional healthcare costs in the U.S.2 The cobas® Cdiff assay provides accurate, on-demand results in just 20 minutes for the detection of toxigenic C. difficile, empowering informed isolation decisions and better management of patients with a suspected C. diff infection. With just three simple steps, the cobas® Cdiff assay can streamline the diagnosis of CDI while providing lab-quality results, empowering informed isolation decisions and better patient management.

cobas® Cdiff specifications

View Full Table

cobas® Cdiff specifications

Instrument

cobas® liat system

Targets

C. difficile Toxin B (tcdB)

Registration

FDA 510(k) cleared, Moderately Complex

Time to result

~20 minutes

Sample type

Unformed stool sample in cobas® PCR media

Reagents

Ready-to-use, pre-packed tube format

Kit Storage

2–8°C

Collection media

cobas® PCR Uni Swab Sample Kit

Technology

Real-time PCR

Sample extraction

Fully automated and integrated

Control

Internal sample processing control, positive and negative controls

cobas® Cdiff ordering information

View Full Table

cobas® Cdiff ordering information

Material Number

Alternative Catalog Number

Material Description

Pack Size

Pack size Description

07454945190   KIT COBAS CDIFF 1 pack 20 tests
07454970190   KIT COBAS CDIFF QC 1 pack 5 sets
07958030190   cobas PCR Media Uni Swab Sample Kit 1 pack 100 uni swab sample packets
<b>cobas</b><sup>®</sup> Cdiff intended use<sup>3</sup>

cobas® Cdiff intended use3

The cobas® Cdiff Nucleic acid test for use on the cobas® liat® system is an automated, qualitative in vitro diagnostic test that uses real-time polymerase chain reaction (PCR) for the detection of the toxin B (tcdB) gene of toxigenic Clostridioides difficile (C. difficile) in unformed (liquid or soft) stool specimens obtained from patients suspected of having C. difficile infection (CDI). The cobas® Cdiff Nucleic acid test for use on the cobas® liat® system is intended for use as an aid in the diagnosis of CDI in humans in conjunction with clinical and epidemiological risk factors.

Would you like to know more about the cobas® Cdiff assay?

Please submit your information in the following form to be contacted by a Roche representative with more details about the cobas® Cdiff assay.

References

  1. Guh AY, Mu Y, Winston LG et al. N Engl J Med 2020;382:1320–30. DOI: 10.1056/NEJMoa1910215.
  2. Desai K, Gupta SB, Dubberke ER et al. Epidemiological and economic burden of Clostridium difficile in the United States: estimates from a modeling approach. BMC Infect Dis2016; 16:303–12.
  3. cobas® Cdiff IVD Instructions for Use

Overview

Detailed Specifications

Ordering Information

Compatible Instruments

...
    ...

    Technical Documents

    error errorMessage
    Sorry, we couldn't find the content you are looking for
    Please try again later